Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC)

Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer

(2017) W Han et al.   ONCOGENE

Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells

(2016) Heimo Syvälä et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide

(2016) Stefan Prekovic et al.   MOLECULAR CANCER THERAPEUTICS

Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer

(2015) C. Liu et al.   CANCER RESEARCH

Statin use and mortality in cancer patients: Systematic review and meta-analysis of observational studies

(2015) Shanliang Zhong et al.   CANCER TREATMENT REVIEWS

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer

(2015) Alejo Rodriguez-Vida et al.   Drug Design Development and Therapy

Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer

(2015) Lauren C. Harshman et al.   JAMA Oncology

Plk1 Inhibition Enhances the Efficacy of Androgen Signaling Blockade in Castration-Resistant Prostate Cancer

(2014) Z. Zhang et al.   CANCER RESEARCH

Cholesteryl Ester Accumulation Induced by PTEN Loss and PI3K/AKT Activation Underlies Human Prostate Cancer Aggressiveness

(2014) Shuhua Yue et al.   Cell Metabolism

Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells

(2014) Yuanyuan Cui et al.   ENDOCRINE-RELATED CANCER

Emerging mechanisms of enzalutamide resistance in prostate cancer

(2014) Frank Claessens et al.   Nature Reviews Urology

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model

(2014) H G Nguyen et al.   ONCOGENE

Overcoming mutation-based resistance to antiandrogens with rational drug design

(2013) Minna D Balbas et al.   eLife

Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years' follow up

(2012) Kashif Shafique et al.   BMC CANCER

Dysregulation of Cholesterol Homeostasis in Human Prostate Cancer through Loss of ABCA1

(2012) B. H. Lee et al.   CANCER RESEARCH

The Importance of LDL and Cholesterol Metabolism for Prostate Epithelial Cell Growth

(2012) Teemu J. Murtola et al.   PLoS One

Lovastatin Causes Diminished PSA Secretion by Inhibiting AR Expression and Function in LNCaP Prostate Cancer Cells

(2011) Lin Yang et al.   UROLOGY

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

(2010) Howard I Scher et al.   LANCET

Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells

(2010) Akira Yokomizo et al.   PROSTATE

Effect of Statins on Serum Prostate-specific Antigen Levels

(2010) Bulent Akduman et al.   UROLOGY

Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor

(2008) Yoshitaka Sekine et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Chinese Red Yeast Rice Versus Lovastatin Effects on Prostate Cancer Cells With and Without Androgen Receptor Overexpression

(2008) Mee Young Hong et al.   JOURNAL OF MEDICINAL FOOD

The Influence of Statin Medications on Prostate-specific Antigen Levels

(2008) Robert J. Hamilton et al.   JNCI-Journal of the National Cancer Institute